The Bone Cancer Treatment Market is segmented by Bone Cancer Type (Osteosarcoma, Chondrosarcoma, Ewing Tumor, and Other Bone Cancer Types] and Secondary Bone Cancer [Metastatic Bone Cancer]), Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, and Other Treatments), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and predictions in value (USD million) for the above segments are included in the report.
The bone cancer treatment market was worth roughly USD 1,158 million in 2020, and it is predicted to grow at a CAGR of 4.9 percent to USD 1,547 million by 2026, with a CAGR of 4.9 percent.
During the early stages of COVID-19, the number of cases treated at musculoskeletal oncology departments decreased significantly, affecting the amount of surgical volumes. The huge decline in musculoskeletal oncology services may have far-reaching implications for patients and the overall market. However, the separate government authorities released several preventative instructions to begin the delayed or postponed bone cancer therapies, establishing
The rising global prevalence of bone cancer, as well as government attempts to raise awareness of the disease, are driving market expansion. The incidence of bone cancer is steadily increasing, and it must be addressed as soon as possible to lessen the global burden of bone sarcoma.
According to the American Society of Clinical Oncology, the United States will see 3,610 new cases of bone cancer in 2021, with a predicted 2,060 fatalities from the disease. The appropriate treatment regime for chemotherapeutic medications licenced for the treatment of bone cancer does not exist since it changes depending on the prevailing conditions and how the patient's body responds to the drug. As a result, the treatment's adverse effects, risks, and limits are limiting the market for bone cancer treatment drugs.
According to the definition, bone cancer is a malignant tumour that develops from cells in the body's bones. It's sometimes called primary bone cancer since it starts in the bones. A tumour that has progressed to the bone area but originated elsewhere is referred to as secondary bone cancer. This study provides a detailed analysis of the bone cancer therapy industry, with a focus on primary bone cancer. The bone cancer treatment market is divided into two categories: primary bone cancer (osteosarcoma, chondrosarcoma, Ewing tumour, and other types of bone cancer) and secondary bone cancer (metastatic bone cancer), as well as treatment types (chemotherapy, targeted therapy, radiation therapy, surgery, and others).
Surgical procedures, treatment schedules, and regular hospital visits have all been disturbed by the COVID-19 epidemic. The COVID-19 pandemic also resulted in a significant shift in the osteosarcoma surgical strategy. Osteosarcoma is predicted to have the greatest market size in the bone cancer type sector of the market, among all primary bone cancers, over the forecast period.
The most frequent type of cancer of the bones is osteosarcoma, which usually affects children and young people. Osteosarcoma is classified as high-, intermediate-, or low-grade based on the cells. According to the American Cancer Society, approximately 800 to 900 new instances of osteosarcoma are identified in the United States each year in 2019, with roughly half of these occurrences happening in children and teenagers.
Various medical centres, university hospitals, and other institutions around the world do osteosarcoma research. In the last few decades, there have been many breakthroughs in the treatment of osteosarcoma. Osteosarcoma can be treated with surgery, radiation therapy, chemotherapy, targeted therapy medications, and other methods. As a result of the high occurrence of osteosarcoma worldwide, research into the bone cancer treatment industry is growing.
Comments
Post a Comment